Pathogenesis, prevention, and treatment of diabetic nephropathy (Q47770839)

5 February 2018

review article

1 reference

title

Pathogenesis, prevention, and treatment of diabetic nephropathy (English)

1 reference

5 February 2018

author name string

M E Cooper

series ordinal

1

1 reference

5 February 2018

language of work or name

English

0 references

publication date

1 July 1998

1 reference

5 February 2018

published in

The Lancet

1 reference

5 February 2018

volume

352

1 reference

5 February 2018

issue

9123

1 reference

5 February 2018

page(s)

213-219

1 reference

5 February 2018

How to protect the kidney in diabetic patients: with special reference to IDDM.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

Prevention of diabetic renal disease with special reference to microalbuminuria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

Patterns of renal injury in NIDDM patients with microalbuminuria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

Insulin resistance in insulin-dependent diabetic patients with microalbuminuria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

Diabetic vascular complications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

Effects of polyol-pathway inhibition and dietary myo-inositol on glomerular hemodynamic function in experimental diabetes mellitus in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Functional and structural studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

Expression of transforming growth factor-beta1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of ACE inhibition.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

Vascular hypertrophy in experimental diabetes. Role of advanced glycation end products

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

Mechanical stretch induces vascular permeability factor in human mesangial cells: mechanisms of signal transduction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

Enhanced G protein activation in IDDM patients with diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

Meta-analysis of association of insertion/deletion polymorphism of angiotensin I-converting enzyme gene with diabetic nephropathy and retinopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

Serum total renin is increased before microalbuminuria in diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

Effect of improved metabolic control on loss of kidney function in type 1 (insulin-dependent) diabetic patients: an update of the Steno studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

Benefits of long-term antihypertensive treatment on prognosis in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

The use of antihypertensive agents in prevention and treatment of diabetic nephropathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme in rats with hypertension and diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

Long-Term Effect of Lisinopril and Atenolol on Kidney Function in Hypertensive NIDDM Subjects With Diabetic Nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. The Microalbuminuria Captopril Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. The Italian Microalbuminuria Study Group in IDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

Effects of long-term enalapril treatment on persistent micro-albuminuria in well-controlled hypertensive and normotensive NIDDM patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

Treatment of hypertensive patients with diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

Detection of microalbuminuria in diabetic patients by urinary dipstick

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

Glomerular lesions and urinary albumin excretion in type I diabetes without overt proteinuria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

Predictive value of microalbuminuria in patients with insulin-dependent diabetes of long duration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

Initiation and progression of diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

Ambulatory blood pressure in the transition from normo- to microalbuminuria. A longitudinal study in IDDM patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

Diabetic nephropathy in type II diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

Glomerular hyperfiltration in microalbuminuric NIDDM patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

Advanced glycosylation end products in diabetic renal and vascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

An agent cleaving glucose-derived protein crosslinks in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

Glucose-induced protein kinase C activation regulates vascular permeability factor mRNA expression and peptide production by human vascular smooth muscle cells in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes: Genetique de la Nephropathie Diabetique (GENEDIAB) study group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

Calcium-channel blockers for hypertension--uncertainty continues

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

Long-term glycemic control and the rate of progression of early diabetic kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

Modelling and costing the consequences of using an ACE inhibitor to slow the progression of renal failure in type I diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

J-curve not burned off by HOT study. Hypertension Optimal Treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

Captopril or conventional therapy in hypertensive type II diabetics. Three-year analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

Diabetic renal disease: the quest for normotension--and beyond

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

Cumulative glycemic exposure and microvascular complications in insulin-dependent diabetes mellitus. The glycemic threshold revisited

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

1 reference

7 January 2021

Differences Between Nisoldipine and Lisinopril on Glomerular Filtration Rates and Albuminuria in Hypertensive IDDM Patients With Diabetic Nephropathy During the First Year of Treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2901346-4

7 January 2021

10.1016/S0140-6736(98)01346-4

Identifiers

DOI

1 reference

5 February 2018

1 reference

5 February 2018